Latest Issue of EPM
Experience. Precision for Radiopharma Logistics. Marken
Winning the race against time with precision for critical Radiopharma shipments.
European Pharmaceutical Manufacturer - Nov/Dec 2024
The Nov/Dec 2024 issue of EPM Magazine explores the latest insights on regulations, manufacturing and testing & inspection, plus a cover story from Tower Cold Chain.
European Pharmaceutical Manufacturer - Sept/Oct 2024
The Sept/Oct 2024 issue of EPM Magazine explores the latest insights on regulations, digital health and coatings plus a cover story from SHL Medical.
European Pharmaceutical Manufacturer - May/June 2024
The May/June 2024 issue of EPM Magazine explores the latest insights on cell & gene therapy, bioprocessing, packaging and manufacturing plus the opinion from AstraZeneca and a cover story from Fette.
European Pharmaceutical Manufacturer - March/April 2024
The March/April 2024 issue of EPM Magazine explores the latest clinical trials insights, a Q&A with Lonza, how automation and robotics are shaping the future, analysing advancing clinical trials manufacturing from pilot to production and more!
European Pharmaceutical Manufacturer - Jan/Feb 2024
The Jan/Feb 2024 issue of European Pharmaceutical Manufacturer explores the latest packaging trends, a Q&A with Lonza, Drug Delivery & Devices, Sustainability, plus Biopharma and Manufacturing insights alongside Element Materials Technologies.
Sponsored Content
A one-stop shop for even the most challenging Monoclonal Antibodies (mAbs)
The biologics market is expanding rapidly – with a compound annual growth rate of 15% predicted until 2027. But this new generation of drugs comes with unique challenges that require an innovative approach underpinned by extensive experience.
12 Mar 2025
08:00
Experience. Precision for Radiopharma Logistics. Marken
Winning the race against time with precision for critical Radiopharma shipments.
Sponsored Content
A one-stop shop for even the most challenging Monoclonal Antibodies (mAbs)
The biologics market is expanding rapidly – with a compound annual growth rate of 15% predicted until 2027. But this new generation of drugs comes with unique challenges that require an innovative approach underpinned by extensive experience.
12 Mar 2025
08:00